Anthem Biosciences block deal: Portsmouth Technologies sells 30 lakh shares worth Rs 250 crore

Portsmouth Technologies LLC sold 30 lakh shares of Anthem Biosciences at Rs 833 apiece in a block deal on the BSE on Friday, October 9, for a total transaction value of Rs 249.90 crore.

According to BSE data, Portsmouth Technologies LLC held 1,53,96,327 shares, representing a 2.73% stake in Anthem Biosciences, as of June 30, 2026. The 30 lakh shares sold represent approximately 19.49% of its holding as of that date.

Assuming no other changes in its shareholding since June 30, Portsmouth's estimated holding after the transaction would stand at 1,23,96,327 shares. Its actual remaining holding would need to be confirmed through updated shareholding disclosures. The buyer's identity was not immediately available.


Shares of Anthem Biosciences closed Friday's trading session at Rs 861.35, down 1.33% from the previous close of Rs 873. The stock traded in a range of Rs 833 to Rs 878.70 during the session. The block deal price was approximately 3.29% below the closing price.

The stock has gained 34.80% so far in 2026, according to BSE analytics. At Friday's closing price, the company's market capitalisation stood at Rs 48,539.49 crore.

ALSO READ: Half of India’s MTF book is in smallcaps; Nithin Kamath flags liquidity risks

Anthem Biosciences reported total income of Rs 443.11 crore for the first quarter of FY27, down 21.3% year-on-year from Rs 563.02 crore.

The company's profit after tax declined 11.7% year-on-year to Rs 119.94 crore from Rs 135.79 crore in the corresponding quarter last year. Profit before tax fell 22.4% to Rs 144.58 crore from Rs 186.25 crore, while earnings per share stood at Rs 2.11, compared with Rs 2.42 a year earlier.

Anthem Biosciences IPO and listing performance

Anthem Biosciences shares made their D-Street debut on Monday, July 21, 2025, following the completion of its initial public offering (IPO), which comprised entirely an offer for sale (OFS). Under the IPO, promoters and existing shareholders offered up to 5.96 crore equity shares, valued at approximately Rs 3,395 crore at the issue price of Rs 570 per share.

The company's shares listed at Rs 723.05 apiece, representing a premium of 26.85% over the IPO issue price.

At Friday's closing price of Rs 861.35, Anthem Biosciences shares were trading at a premium of approximately 51.11% over the IPO issue price of Rs 570 per share.

Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here